Group 1: AI in Healthcare Development - The integration of AI in healthcare is driven by policy support and technological advancements, enhancing clinical decision-making and optimizing treatment processes[3] - By 2027, the goal is to establish high-quality healthcare data sets and specialized AI models for clinical decision support, with full coverage of AI-assisted primary care by 2030[12] - The global market for healthcare AI solutions is projected to reach 40 billion CNY by 2024, with China's market expected to reach 16.4 billion CNY in the same year[21][22] Group 2: Market Performance and Trends - The North Exchange's pharmaceutical and biotechnology sector saw a weekly increase of 0.34%, with traditional Chinese medicine rising by 1.15%[4] - As of February 27, 2026, there are 170 companies queued for listing on the North Exchange, with 14 in the pharmaceutical and biotechnology sector, averaging 438 million CNY in revenue for 2024[41] - 59.09% of pharmaceutical and biotechnology stocks experienced price increases this week, with notable gains from companies like Aisheren (+3.55%) and Senxuan Pharmaceutical (+2.34%)[36][39] Group 3: Company Performance Highlights - Jin Hao Medical, Wuxi Crystal Sea, and Deyuan Pharmaceutical reported significant net profit growth exceeding 10% year-on-year for 2025[4] - Baijing Biological achieved a revenue of 402 million CNY in 2024, with a net profit of 123.83 million CNY, reflecting a year-on-year growth of 18.91%[43] - Kanghua Co., Ltd. reported a revenue of 728 million CNY in 2024, with a net profit of 125.07 million CNY, marking a 79.09% increase year-on-year[50]
北交所策略专题报告：AI+医疗渗透提升项自主智能体升级，掘金北交所AI诊疗标的
KAIYUAN SECURITIES·2026-03-01 10:24